Abbott Abbokinase
Additional manufacturing deficiencies found during inspections of Abbott and the company's supplier of human kidney cells, BioWittaker, FDA said in a July 16 "Talk Paper." FDA has sent a letter to Abbott identifying "numerous significant deviations from current good manufacturing practices." Abbott may not distribute Abbokinase (urokinase) until the company completes investigations of reovirus and mycoplasm contamination, including the source of human kidney cells and validates manufacturing processes. The agency conducted the inspections after a January letter to health care professionals alerting physicians of the risk of transmitting infectious agents (1"The Pink Sheet" March 22, In Brief)
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




